Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2014 / Nov / The IFCC Vision
Regulation and standards Training and education Profession Professional Development

The IFCC Vision

IFCC President Graham Beastall offers his overarching perspective on the importance of its task forces.

By Graham Beastall 11/19/2014 1 min read

Share

Graham Beastall

What are IFCC task forces and why were they formed? A task force is made up of a panel of international experts spanning many different disciplines (for example, laboratory managers, geneticists, pathologists, regulators, analytical scientists), to address a broad, contemporary issue that is relevant to the laboratory medicine and clinical chemistry community. The IFCC structures its activities around three specific areas: science, education, and management. Around 10 years ago, we realized that many of our activities straddled all three, which led to the formation of our very first task force – ethics in laboratory medicine. Eleven task forces now exist, each with the aim of identifying issues, providing guidance and best practice support, and promoting international collaboration. We’re continuously under pressure to ensure the clinical relevance of what our laboratories do, and collaboration with international clinical organizations has become a high priority for us. The task forces offer the best way to do this and through them, we aim to facilitate harmonization of high quality laboratory practices, which results in improved clinical outcomes and patient safety.

What have been some of the biggest successes? There are three that instantly come to mind. The task force for chronic kidney disease (CKD) is doing some great work for developing countries – they’re providing guidance on how to estimate glomerular filtration rate, to report it in standard ways, and to encourage collaboration with  national renal organizations. This is making a positive difference to huge numbers of patients with CKD. Millions of diabetes patients worldwide are benefiting from the work of the task force for implementation of HbA1c standardization, which is working with manufacturers to ensure all HbA1c methods are aligned to the global standard. They’re also collaborating with the International Diabetes Federation, IFCC member societies and national diabetes societies to agree reporting criteria and action limits.

I’m also very pleased with the achievements of the task force for young scientists, which has identified hundreds of senior trainees in laboratory medicine from scores of countries around the world. By networking these young scientists through social media they’re identifying common issues (such as training standards) and communicating successes and achievements. Tomorrow’s leaders will have something in common – and a network of friends.

What broad challenges has the IFCC faced? As with any international project the challenge is to get a high level of engagement and then to find a way forward that attracts unanimous support. The level of engagement is rising as the quality of laboratory medicine improves in developing countries, but unanimity of support is not always possible. For example, practice in Europe and the USA may differ, or some recommendations are beyond the resources of some countries.

What further success can we expect? We have to be realistic about our expectations – international projects generally progress slowly. However, with modern communication methods it is possible to reach large numbers of people in an interactive manner. Experience has shown that a small number of charismatic ‘champions’ can be more effective in delivering positive outcomes than dry scientific publications (no matter how authoritative). As a society, we benefit hugely from talented volunteers who give freely of their time and expertise in the interests of international harmonization – we have to be optimistic!

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Graham Beastall

More Articles by Graham Beastall

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Microbiology and climate change: Building a sustainable future together
Regulation and standards
Microbiology and climate change: Building a sustainable future together

January 27, 2022

1 min read

Playing Chicken With Chicken
Regulation and standards
Playing Chicken With Chicken

October 21, 2016

1 min read

Why is antibiotic resistance in Campylobacter species on the rise – and how can we combat it?

A Pig In a Poke
Regulation and standards
A Pig In a Poke

October 21, 2016

1 min read

When importing livestock for food or breeding, European countries may inadvertently open their borders to superbugs as well

Sneaky Superbugs
Regulation and standards
Sneaky Superbugs

October 21, 2016

1 min read

Norway’s strict LA-MRSA transmission measures prevent the import of almost all live pigs – but the bacteria have found a new way in

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.